Skip to main content
SpringerLink
Log in

Antineoplastics

Lack of efficacy, off-label use and various toxicities: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Jonsdottir G, et al. Activity of osimertinib in a patient with stage IV non-small cell lung cancer harboring HER2 exon 19, p.L755P mutation: case report. Translational Lung Cancer Research 12 : 927-932, No. 4, Jan 2023. Available from: URL: https://tlcr.amegroups.com/article/view/73740/pdf

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Antineoplastics. Reactions Weekly 1967, 47 (2023). https://doi.org/10.1007/s40278-023-43854-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-43854-5

Search

Navigation